Bajaj Healthcare has received Establishment Inspection Report (EIR) from the United State Food and Drug Administration (USFDA), for the Pre-approval inspection that was carried out by the USFDA in November, 2022 at its API manufacturing facility in Savli, Vadodara, Gujarat, with Zero 483 observations (No inspectional observations).
The receipt of the Establishment Inspection Report signifies the successful conclusion of the inspection. It serves as a testament to its dedication to upholding global standards of quality and compliance
Bajaj Healthcare mainly focuses on development, manufacturing and supply of Amino Acids, Nutritional Supplements and Active Pharmaceutical Ingredients (API) for Pharmaceutical, Nutraceuticals and Food industries.
